- Home
- AIRE vs UNCY Comparison
AIRE vs UNCY Comparison
Compare AIRE & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRE
- UNCY
- Stock Information
- Founded
- AIRE 2021
- UNCY 2016
- Country
- AIRE United States
- UNCY United States
- Employees
- AIRE N/A
- UNCY N/A
- Industry
- AIRE
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- AIRE
- UNCY Health Care
- Exchange
- AIRE Nasdaq
- UNCY Nasdaq
- Market Cap
- AIRE 86.1M
- UNCY 78.1M
- IPO Year
- AIRE N/A
- UNCY 2021
- Fundamental
- Price
- AIRE $0.58
- UNCY $0.60
- Analyst Decision
- AIRE Strong Buy
- UNCY Strong Buy
- Analyst Count
- AIRE 1
- UNCY 3
- Target Price
- AIRE $3.00
- UNCY $5.50
- AVG Volume (30 Days)
- AIRE 1.8M
- UNCY 652.3K
- Earning Date
- AIRE 05-16-2025
- UNCY 05-14-2025
- Dividend Yield
- AIRE N/A
- UNCY N/A
- EPS Growth
- AIRE N/A
- UNCY N/A
- EPS
- AIRE N/A
- UNCY N/A
- Revenue
- AIRE $1,853,629.00
- UNCY N/A
- Revenue This Year
- AIRE $206.83
- UNCY N/A
- Revenue Next Year
- AIRE $158.08
- UNCY $1,410.65
- P/E Ratio
- AIRE N/A
- UNCY N/A
- Revenue Growth
- AIRE 1925.60
- UNCY N/A
- 52 Week Low
- AIRE $0.52
- UNCY $0.20
- 52 Week High
- AIRE $4.49
- UNCY $1.16
- Technical
- Relative Strength Index (RSI)
- AIRE 36.67
- UNCY 49.52
- Support Level
- AIRE $0.57
- UNCY $0.50
- Resistance Level
- AIRE $0.72
- UNCY $0.62
- Average True Range (ATR)
- AIRE 0.04
- UNCY 0.05
- MACD
- AIRE 0.02
- UNCY -0.01
- Stochastic Oscillator
- AIRE 26.04
- UNCY 56.41
About AIRE reAlpha Tech Corp.
ReAlpha Tech Corp is a real estate technology company that develops and utilizes its artificial intelligence-focused technology stack to empower retail investor participation in short-term rental properties, which are real estate units listed for a rental term. It provides short-term rental investment opportunities to everyday investors. The company has developed technologies and tools that allow for analysis of short-term rental properties using AI to provide insight into that property's potential profitability and ways to increase such profitability; and has an app for investment into the properties that it purchased aimed at retail investors. The company's reportable segments are; Platform Services, which derives key revenue, and the Rental business segment.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.